Beikang Medical performance will grow steadily
Posted: Mon Jan 20, 2025 6:56 am
Sales expectations are achieved, and the advantages of the global industrial chain are beginning to show results
In an era of sluggish sentiment in the medical sector, Beikang Medical's announcement of exceeding sales expectations for 2024 is exciting.
Recently, Beikang Medical, the first assisted reproductive IVD company focusing on the entire reproductive health industry chain, released its unaudited operating report card for 2024, achieving annual revenue of approximately 300 million yuan, a year-on-year surge of more than 40%, marking its internationalization The strategic deployment of the entire industry chain has achieved initial results, and it is expected to grow into the most innovative enterprise in the field of assisted reproduction in the world.
Revenue increased by more than 40% against the trend, realizing a closed loop of the entire industry chain in the reproductive field
Through years of R&D investment in the field of assisted reproduction, Beikang Medical has led the trinity of innovation model around "original innovation + global mergers and acquisitions + digital intelligence", and has built internationally leading embryology laboratories, genetic laboratories, andrology laboratories around the world. Laboratory thailand whatsapp mobile phone number list and cryogenic storage laboratory solutions. At the same time, the company combines the clinical application of artificial intelligence in assisted reproduction and connects all laboratory hardware equipment to the iARMS electronic medical record system to provide reproductive centers with overall upgrades and solutions for "intelligent" reproductive centers.
In 2024, Beikang Medical will obtain medical device registration certificates for a number of major equipment and complete the ramp-up period from corporate innovative products to registered products. It will further strengthen the company's competitiveness, expand the company's product pipeline, optimize the company's sales costs, and significantly Enhance the brand influence and industry status of Beikang Medical in the global assisted reproductive field.
DA5000 high-throughput gene sequencer approved
In 2024, the DA5000 high-throughput gene sequencer independently developed by Beikang Medical was approved as a national Class III medical device registration certificate.
In an era of sluggish sentiment in the medical sector, Beikang Medical's announcement of exceeding sales expectations for 2024 is exciting.
Recently, Beikang Medical, the first assisted reproductive IVD company focusing on the entire reproductive health industry chain, released its unaudited operating report card for 2024, achieving annual revenue of approximately 300 million yuan, a year-on-year surge of more than 40%, marking its internationalization The strategic deployment of the entire industry chain has achieved initial results, and it is expected to grow into the most innovative enterprise in the field of assisted reproduction in the world.
Revenue increased by more than 40% against the trend, realizing a closed loop of the entire industry chain in the reproductive field
Through years of R&D investment in the field of assisted reproduction, Beikang Medical has led the trinity of innovation model around "original innovation + global mergers and acquisitions + digital intelligence", and has built internationally leading embryology laboratories, genetic laboratories, andrology laboratories around the world. Laboratory thailand whatsapp mobile phone number list and cryogenic storage laboratory solutions. At the same time, the company combines the clinical application of artificial intelligence in assisted reproduction and connects all laboratory hardware equipment to the iARMS electronic medical record system to provide reproductive centers with overall upgrades and solutions for "intelligent" reproductive centers.
In 2024, Beikang Medical will obtain medical device registration certificates for a number of major equipment and complete the ramp-up period from corporate innovative products to registered products. It will further strengthen the company's competitiveness, expand the company's product pipeline, optimize the company's sales costs, and significantly Enhance the brand influence and industry status of Beikang Medical in the global assisted reproductive field.
DA5000 high-throughput gene sequencer approved
In 2024, the DA5000 high-throughput gene sequencer independently developed by Beikang Medical was approved as a national Class III medical device registration certificate.